Marc LaForce, the director of the Meningitis Vaccine Project, recently spoke about the successes of the new MenAfriVac vaccine during a National Institutes of Health presentation.

LaForce worked with the National Institutes of Health and the MVP, a partnership between the World Health Organization and the Program for Appropriate Technology in Health, for close to a decade to develop a cost-effective vaccine for Group A meningococcal disease. Within a few years, the disease was developed and distributed to more than 10 million people.

Read more.